Eli Lilly and Company Announced Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes

Apr. 21 | Eli Lilly and Company announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. Primary...

FDA Approved INVOKANA, The new Diabetes Drug

Apr. 12 | Janssen Pharmaceuticals, Inc. communicated that the U.S. Food and Drug Administration (FDA) approved INVOKANA (canagliflozin) for the treatment of adults with type 2 diabetes. INVOKANA is the first in a new class of medications called sodium glucose co-transporter...

Melatonin Predicts Type 2 Diabetes Risk

Apr. 12 | Type 2 diabetes risk has long been linked to sleep abnormalities, and a new study conducted at Brigham and Women’s Hospital (BWH) in Boston finds that low melatonin secretion is associated with increased risk for the disease. The study was published...

Diabetes Drug Lyxumia Approved In Europe

Feb. 14 | Sanofi communicated that the European Commission granted Marketing Authorisation in Europe for Lyxumia (lixisenatide). Lyxumia, the first once-daily prandial GLP-1 receptor agonist, is indicated for the treatment of adults with type 2 diabetes mellitus...

FDA Approved Nesina, Kazano, And Oseni Of Takeda For Type 2 Diabetes

Jan. 28 | The U.S. Food and Drug Administration (FDA) approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride)...

Black Tea And Diabetes Risk

Dec. 18 | According to a new study, rates of type 2 diabetes are lower in countries where many people drink black tea, a finding that supports previous research suggesting that regular consumption of black tea is associated with a reduced risk of diabetes. Researcher...

Merck’s Once-A-Week Diabetes Drug Effective In Study

Oct. 8 | Merck has announced that Phase IIb data for MK-3102, the company’s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes. MK-3102 significantly lowered blood sugar in this 12-week study compared with placebo,...

FDA Approved Levemir For Younger Kids

Jul. 5 | The U.S. Food and Drug Administration (FDA) approved Levemir® (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes. It is being marketed by Novo Nordisk, a world leader in diabetes care. With the expansion...

FDA Approved BELVIQ, The Obesity Drug In 13 Years

Jun. 29 | The U.S. Food and Drug Administration (FDA) approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2or...

High-Fat Diet Good For Type-2 Diabetics

Jun. 25 | A new research found that food with a lot of fat and few carbohydrates may actually benefit type-2 diabetics who are advised to stick to a low-fat diet. The results of a two-year dietary study led by Hans Guldbrand, general practitioner, and Fredrik Nystrom,...